Sep 12 |
Gilead Sciences goes ex-dividend tomorrow
|
Sep 12 |
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
|
Sep 12 |
Gilead Unveils More Positive Data on HIV Prevention Shot
|
Sep 12 |
Gilead Stock Rises on Positive Study Results for Twice-Yearly HIV Drug
|
Sep 12 |
Gilead says HIV prevention injection reduced cases by 96%, sending shares higher
|
Sep 12 |
Helping End HIV - Gilead Sciences
|
Sep 12 |
Gilead posts second late-stage win for twice-yearly HIV therapy
|
Sep 12 |
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
|
Sep 11 |
Gilead and Genesis partner to create novel therapies using AI
|
Sep 11 |
Gilead Sciences, Inc. (GILD) Baird Global Healthcare Conference (Transcript)
|